Relmada Therapeutics Inc
NASDAQ:RLMD
Balance Sheet
Balance Sheet Decomposition
Relmada Therapeutics Inc
Relmada Therapeutics Inc
Balance Sheet
Relmada Therapeutics Inc
| Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Cash & Cash Equivalents |
36
|
3
|
44
|
5
|
4
|
4
|
|
| Cash Equivalents |
36
|
3
|
44
|
5
|
4
|
4
|
|
| Short-Term Investments |
80
|
115
|
168
|
143
|
92
|
41
|
|
| Total Receivables |
0
|
0
|
0
|
1
|
0
|
0
|
|
| Other Current Assets |
0
|
1
|
11
|
4
|
1
|
1
|
|
| Total Current Assets |
117
|
118
|
223
|
153
|
98
|
46
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
117
N/A
|
118
+1%
|
223
+89%
|
153
-32%
|
98
-36%
|
46
-53%
|
|
| Liabilities | |||||||
| Accounts Payable |
1
|
8
|
11
|
5
|
4
|
4
|
|
| Accrued Liabilities |
1
|
4
|
4
|
7
|
9
|
6
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
2
|
13
|
15
|
13
|
12
|
10
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
2
N/A
|
13
+740%
|
15
+20%
|
13
-17%
|
12
-2%
|
10
-16%
|
|
| Equity | |||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
120
|
179
|
305
|
462
|
561
|
641
|
|
| Additional Paid In Capital |
236
|
285
|
513
|
603
|
646
|
676
|
|
| Total Equity |
116
N/A
|
106
-9%
|
208
+97%
|
140
-33%
|
85
-39%
|
36
-58%
|
|
| Total Liabilities & Equity |
117
N/A
|
118
+1%
|
223
+89%
|
153
-32%
|
98
-36%
|
46
-53%
|
|
| Shares Outstanding | |||||||
| Common Shares Outstanding |
15
|
16
|
28
|
30
|
30
|
30
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
|